Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mirko Rehberg

Showing results (31-40 of 42) with videos related to

Pageof 5
Sort By:
EMBO Molecular Medicine|June 9, 2023
TAPT1-at the crossroads of extracellular matrix and signaling in Osteogenesis imperfectaJulia Etich, Oliver Semler, Nicola L Stevenson, et al.
Pediatric Nephrology (Berlin, Germany)|June 24, 2024
Health-related quality of life of children with X-linked hypophosphatemia in GermanyMartin Klein, Michael Obermaier, Helena Mutze, et al.
The Journal of Clinical Endocrinology and Metabolism|April 25, 2023
Effects of Burosumab Treatment on Mineral Metabolism in Children and Adolescents With X-linked HypophosphatemiaAnnika Ewert, Mirko Rehberg, Karl Peter Schlingmann, et al.
BMJ Open|June 4, 2024
An exploratory open-label multicentre phase I/II trial evaluating the safety and efficacy of postnatal or prenatal and postnatal administration of allogeneic expanded fetal mesenchymal stem cells for the treatment of severe osteogenesis imperfecta in infants and fetuses: the BOOSTB4 trial protocolRachel L Sagar, Eva Åström, Lyn S Chitty, et al.
Calcified Tissue International|March 28, 2025
Office Blood Pressure and Obesity in Children with X-Linked HypophosphatemiaIneke Böckmann, Maren Leifheit-Nestler, Mirko Rehberg, et al.
Orphanet Journal of Rare Diseases|March 16, 2023
Lifetime impact of achondroplasia study in Europe (LIAISE): findings from a multinational observational studyMohamad Maghnie, Oliver Semler, Encarna Guillen-Navarro, et al.
Medrxiv : the Preprint Server for Health Sciences|May 19, 2025
Linking international registries to FHIR and Phenopackets with RareLink: a scalable REDCap-based framework for rare disease data interoperabilityAdam S L Graefe, Filip Rehburg, Samer Alkarkoukly, et al.
NPJ Genomic Medicine|November 18, 2025
RareLink: scalable REDCap-based framework for rare disease interoperability linking international registries to FHIR and PhenopacketsAdam S L Graefe, Filip Rehburg, Samer Alkarkoukly, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|April 25, 2026
Markers and regulators of osteoblast and osteoclast activity in children with X-linked hypophosphatemia treated with burosumabIneke Böckmann, Maren Leifheit-Nestler, Mirko Rehberg, et al.
Pediatric Nephrology (Berlin, Germany)|June 10, 2025
Growth dynamics of transversal body dimensions and proportions, with related clinical determinants in children with X-linked hypophosphatemia treated with phosphate supplements and active vitamin DLaura Celine Brieger, Stephan Przygodda, Alina Verena Bohlen, et al.
Pageof 5

Showing results (31-40 of 42) with videos related to

Sort By:
Pageof 5
EMBO Molecular Medicine|June 9, 2023
TAPT1-at the crossroads of extracellular matrix and signaling in Osteogenesis imperfectaJulia Etich, Oliver Semler, Nicola L Stevenson, et al.
Pediatric Nephrology (Berlin, Germany)|June 24, 2024
Health-related quality of life of children with X-linked hypophosphatemia in GermanyMartin Klein, Michael Obermaier, Helena Mutze, et al.
The Journal of Clinical Endocrinology and Metabolism|April 25, 2023
Effects of Burosumab Treatment on Mineral Metabolism in Children and Adolescents With X-linked HypophosphatemiaAnnika Ewert, Mirko Rehberg, Karl Peter Schlingmann, et al.
BMJ Open|June 4, 2024
An exploratory open-label multicentre phase I/II trial evaluating the safety and efficacy of postnatal or prenatal and postnatal administration of allogeneic expanded fetal mesenchymal stem cells for the treatment of severe osteogenesis imperfecta in infants and fetuses: the BOOSTB4 trial protocolRachel L Sagar, Eva Åström, Lyn S Chitty, et al.
Calcified Tissue International|March 28, 2025
Office Blood Pressure and Obesity in Children with X-Linked HypophosphatemiaIneke Böckmann, Maren Leifheit-Nestler, Mirko Rehberg, et al.
Orphanet Journal of Rare Diseases|March 16, 2023
Lifetime impact of achondroplasia study in Europe (LIAISE): findings from a multinational observational studyMohamad Maghnie, Oliver Semler, Encarna Guillen-Navarro, et al.
Medrxiv : the Preprint Server for Health Sciences|May 19, 2025
Linking international registries to FHIR and Phenopackets with RareLink: a scalable REDCap-based framework for rare disease data interoperabilityAdam S L Graefe, Filip Rehburg, Samer Alkarkoukly, et al.
NPJ Genomic Medicine|November 18, 2025
RareLink: scalable REDCap-based framework for rare disease interoperability linking international registries to FHIR and PhenopacketsAdam S L Graefe, Filip Rehburg, Samer Alkarkoukly, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|April 25, 2026
Markers and regulators of osteoblast and osteoclast activity in children with X-linked hypophosphatemia treated with burosumabIneke Böckmann, Maren Leifheit-Nestler, Mirko Rehberg, et al.
Pediatric Nephrology (Berlin, Germany)|June 10, 2025
Growth dynamics of transversal body dimensions and proportions, with related clinical determinants in children with X-linked hypophosphatemia treated with phosphate supplements and active vitamin DLaura Celine Brieger, Stephan Przygodda, Alina Verena Bohlen, et al.
Pageof 5